AbbVie | pharmaphorum

Skip to main content

Saturday 25 July 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

AbbVie

News

Merck-sign

Regulators finally back Merck KGaA oral MS drug

A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.

News

AbbVieHQ

AbbVie looks beyond Humira as RA pill meets phase 3 targets

Upadacitinib hopes drug will reduce reliance on Humira.

News

French pharma company Sanofi

Sanofi, Regeneron aim to undercut rivals with new RA drug

New drug will be sold at around 30% discount to rivals.

News

AbbVie-sign

AbbVie’s 8-week hepatitis C drug granted early access in UK

AbbVie’s hepatitis C drug granted early access in UK

News

Hepatitis Virus - 3d rendered illustration

AbbVie takes aim at Gilead and BMS with 8-week hep C treatme...

Trial backs patient-friendly regime in tough to treat strain.

News

AbbVie-HQ

Doubts over AbbVie PARP inhibitor after double trial failure

Veliparib fails in two phase 3 trials.

Load more results

Editor's Picks

Novo's Wegovy pill cleared for weight loss in EU

Lilly buys into psychedelics with $3.8bn AtaiBeckley deal

Bayer's Kerendia on course for NHS use in heart failure

MSD gets first FDA okay for oral PCSK9 cholesterol drug

GSK abandons cough drug added in $2bn Bellus deal

News

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company